Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Apr 25;24(1):137.
doi: 10.1186/s12883-024-03645-9.

Guillain-Barre syndrome following scrub typhus: a case report and literature review

Shijun Hu #  1 , Zhichuan Lin #  1 , Tao Liu  1 , Shixiong Huang  1 , Hui Liang  2
Affiliations
Review

Guillain-Barre syndrome following scrub typhus: a case report and literature review

Shijun Hu et al. BMC Neurol. .

Abstract

Background: Scrub typhus is an acute infectious disease caused by Orientia tsutsugamushi. Guillain-Barre syndrome (GBS) is an autoimmune-mediated peripheral neuropathy with a frequent history of prodromal infections, but GBS associated with scrub typhus is very rare.

Case presentation: We report a 51-year-old male patient who developed dysarthria and peripheral facial paralysis following the cure of scfrub typhus. CSF examination and electrophysiological findings suggested a diagnosis of GBS. After treatment with intravenous immunoglobulin, the patient's neurological condition improved rapidly.

Conclusions: Scrub typhus infection is likely to be a potential predisposing factor in GBS, while scrub typhus-associated GBS has a favorable prognosis.

Keywords: Anti-sulfatide antibodies; Case report; Guillain–Barré syndrome; Neuropathy; Scrub typhus.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

Similar articles

See all similar articles

References

    1. Musa TH, Ahmad T, Wana MN, Li W, Musa HH, Sharun K, et al. The epidemiology, diagnosis and management of scrub typhus disease in China. Hum Vaccines Immunother. 2021;17:3795–805. doi: 10.1080/21645515.2021.1934355. - DOI - PMC - PubMed
    1. Papri N, Islam Z, Leonhard SE, Mohammad QD, Endtz HP, Jacobs BC. Guillain-Barre syndrome in low-income and middle-income countries: challenges and prospects. Nat Rev Neurol. 2021;17:285–96. doi: 10.1038/s41582-021-00467-y. - DOI - PMC - PubMed
    1. Meehan GR, McGonigal R, Cunningham ME, Wang Y, Barrie JA, Halstead SK, et al. Differential binding patterns of anti-sulfatide antibodies to glial membranes. J Neuroimmunol. 2018;323:28–35. doi: 10.1016/j.jneuroim.2018.07.004. - DOI - PMC - PubMed
    1. Rinaldi S, Brennan KM, Kalna G, Walgaard C, van Doorn P, Jacobs BC, et al. Antibodies to heteromeric glycolipid complexes in Guillain-Barre syndrome. PLoS ONE. 2013;8:e82337. doi: 10.1371/journal.pone.0082337. - DOI - PMC - PubMed
    1. Dabby R, Weimer LH, Hays AP, Olarte M, Latov N. Antisulfatide antibodies in neuropathy: clinical and electrophysiologic correlates. Neurology. 2000;54:1448–52. doi: 10.1212/WNL.54.7.1448. - DOI - PubMed

Substances